Home > > > > > Report Detail

Hepatitis Drug Development Pipeline Review, 2018

Publisher Name :
Date: 29-Jun-2018
No. of pages: 133

Hepatitis Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for hepatitis infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, hepatitis B, hepatitis D and hepatitis E, and features dormant and discontinued products.

Hepatitis refers to inflammation of the liver and is most commonly caused by viral infections. Hepatitis A and E are typically caused by ingestion of contaminated food or water. Symptoms of hepatitis A infection include fatigue, nausea and vomiting, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes.

Risk factors include a weakened immune system and use of injected or non-injected illicit drugs. Symptoms of hepatitis E include yellowing of the skin, dark urine, fever, fatigue, joint pain, nausea, a loss of appetite and pain in the abdomen.

Hepatitis B and hepatitis D infection typically occur as a result of contact with infected body fluids. Transmission of hepatitis B can occur via sexual contact, injection drug use or transfusions of contaminated blood and blood products. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes, dark urine, extreme fatigue, nausea, vomiting and abdominal pain.

Hepatitis D infection only occurs in persons previously infected with hepatitis B, as the hepatitis D virus can only replicate in the presence of hepatitis B. The co-infection of hepatitis B and hepatitis D is associated with greater disease severity than hepatitis B infection alone.

Companies operating in this pipeline space include Cadila Healthcare and Chongqing Zhifei Biological Products.

Scope

- Which companies are the most active within each pipeline?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Hepatitis Drug Development Pipeline Review, 2018

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Hepatitis Report Coverage 8
2.2 Hepatitis A - Overview 8
2.3 Hepatitis B - Overview 8
2.4 Hepatitis D - Overview 8
2.5 Hepatitis E - Overview 8
3 Therapeutics Development 9
3.1 Hepatitis A 9
3.2 Hepatitis B 12
3.3 Hepatitis D 27
3.4 Hepatitis E 30
4 Therapeutics Assessment 33
4.1 Hepatitis A 33
4.2 Hepatitis B 35
4.3 Hepatitis D 44
4.4 Hepatitis E 49
5 Companies Involved in Therapeutics Development 52
5.1 Hepatitis A 52
5.2 Hepatitis B 54
5.3 Hepatitis D 95
5.4 Hepatitis E 98
6 Dormant Projects 101
6.1 Hepatitis A 101
6.2 Hepatitis B 102
6.3 Hepatitis D 108
6.4 Hepatitis E 108
7 Discontinued Products 109
7.1 Hepatitis B 109
8 Product Development Milestones 110
8.1 Hepatitis B 110
8.2 Hepatitis D 122
8.3 Hepatitis E 131
9 Appendix 132
9.1 Methodology 132
9.2 Coverage 132
9.3 Secondary Research 132
9.4 Primary Research 132
9.5 Expert Panel Validation 132
9.6 Contact Us 133
9.7 Disclaimer 133

1.1 List of Tables
Table 1: Number of Products under Development for Hepatitis A 9
Table 2: Number of Products under Development by Companies, Hepatitis A 10
Table 3: Number of Products under Development by Universities/Institutes, Hepatitis A 11
Table 4: Products under Development by Companies, Hepatitis A 11
Table 5: Products under Development by Universities/Institutes, Hepatitis A 11
Table 6: Number of Products under Development for Hepatitis B 12
Table 7: Number of Products under Development by Companies, Hepatitis B 14
Table 8: Number of Products under Development by Universities/Institutes, Hepatitis B 17
Table 9: Products under Development by Companies, Hepatitis B 18
Table 10: Products under Development by Universities/Institutes, Hepatitis B 26
Table 11: Number of Products under Development for Hepatitis D 27
Table 12: Number of Products under Development by Companies, Hepatitis D 28
Table 13: Number of Products under Development by Universities/Institutes, Hepatitis D 29
Table 14: Products under Development by Companies, Hepatitis D 29
Table 15: Products under Development by Universities/Institutes, Hepatitis D 29
Table 16: Number of Products under Development for Hepatitis E 30
Table 17: Number of Products under Development by Companies, Hepatitis E 31
Table 18: Number of Products under Development by Universities/Institutes, Hepatitis E 32
Table 19: Products under Development by Companies, Hepatitis E 32
Table 20: Products under Development by Universities/Institutes, Hepatitis E 32
Table 21: Number of Products by Stage and Route of Administration, Hepatitis A 33
Table 22: Number of Products by Stage and Molecule Type, Hepatitis A 35
Table 23: Number of Products by Stage and Target, Hepatitis B 36
Table 24: Number of Products by Stage and Mechanism of Action, Hepatitis B 39
Table 25: Number of Products by Stage and Route of Administration, Hepatitis B 41
Table 26: Number of Products by Stage and Molecule Type, Hepatitis B 43
Table 27: Number of Products by Stage and Target, Hepatitis D 45
Table 28: Number of Products by Stage and Mechanism of Action, Hepatitis D 46
Table 29: Number of Products by Stage and Route of Administration, Hepatitis D 48
Table 30: Number of Products by Stage and Molecule Type, Hepatitis D 49
Table 31: Number of Products by Stage and Target, Hepatitis E 49
Table 32: Number of Products by Stage and Mechanism of Action, Hepatitis E 50
Table 33: Number of Products by Stage and Route of Administration, Hepatitis E 50
Table 34: Number of Products by Stage and Molecule Type, Hepatitis E 51
Table 35: Hepatitis A - Pipeline by Beijing Minhai Biotechnology Co Ltd 52
Table 36: Hepatitis A - Pipeline by Cadila Healthcare Ltd 52
Table 37: Hepatitis A - Pipeline by China National Pharmaceutical Group Corp 53
Table 38: Hepatitis A - Pipeline by Indian Immunologicals Ltd 53
Table 39: Hepatitis A - Pipeline by Sinovac Biotech Ltd 54
Table 40: Hepatitis B - Pipeline by Abivax SA 54
Table 41: Hepatitis B - Pipeline by AiCuris GmbH & Co KG 55
Table 42: Hepatitis B - Pipeline by AIMM Therapeutics BV 55
Table 43: Hepatitis B - Pipeline by Akshaya Bio Inc 56
Table 44: Hepatitis B - Pipeline by Alnylam Pharmaceuticals Inc 56
Table 45: Hepatitis B - Pipeline by Altimmune Inc 57
Table 46: Hepatitis B - Pipeline by Altravax Inc 57
Table 47: Hepatitis B - Pipeline by Amarna Therapeutics BV 58
Table 48: Hepatitis B - Pipeline by Arbutus Biopharma Corp 58
Table 49: Hepatitis B - Pipeline by Arcturus Therapeutics Ltd 59
Table 50: Hepatitis B - Pipeline by Arrowhead Pharmaceuticals Inc 59
Table 51: Hepatitis B - Pipeline by Ascentage Pharma Group Corp Ltd 60
Table 52: Hepatitis B - Pipeline by Assembly Biosciences Inc 60
Table 53: Hepatitis B - Pipeline by Aucta Pharmaceuticals LLC 61
Table 54: Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd 61
Table 55: Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd 62
Table 56: Hepatitis B - Pipeline by Benitec Biopharma Ltd 62
Table 57: Hepatitis B - Pipeline by Biological E Ltd 63
Table 58: Hepatitis B - Pipeline by BioStar Pharmaceuticals Inc 63
Table 59: Hepatitis B - Pipeline by Biotron Ltd 64
Table 60: Hepatitis B - Pipeline by Bolder Biotechnology Inc 64

1.2 List of Figures
Figure 1: Number of Products under Development for Hepatitis A 9
Figure 2: Number of Products under Development by Companies, Hepatitis A 10
Figure 3: Number of Products under Development for Hepatitis B 12
Figure 4: Number of Products under Development by Companies, Hepatitis B 13
Figure 5: Number of Products under Development by Universities/Institutes, Hepatitis B 17
Figure 6: Number of Products under Development for Hepatitis D 27
Figure 7: Number of Products under Development by Companies, Hepatitis D 28
Figure 8: Number of Products under Development for Hepatitis E 30
Figure 9: Number of Products under Development by Companies, Hepatitis E 31
Figure 10: Number of Products by Stage and Routes of Administration, Hepatitis A 33
Figure 11: Number of Products by Molecule Types, Hepatitis A 34
Figure 12: Number of Products by Stage and Molecule Types, Hepatitis A 34
Figure 13: Number of Products by Top 10 Targets, Hepatitis B 35
Figure 14: Number of Products by Stage and Top 10 Targets, Hepatitis B 36
Figure 15: Number of Products by Top 10 Mechanism of Actions, Hepatitis B 38
Figure 16: Number of Products by Stage and Top 10 Mechanism of Actions, Hepatitis B 38
Figure 17: Number of Products by Routes of Administration, Hepatitis B 40
Figure 18: Number of Products by Stage and Routes of Administration, Hepatitis B 41
Figure 19: Number of Products by Top 10 Molecule Types, Hepatitis B 42
Figure 20: Number of Products by Stage and Top 10 Molecule Types, Hepatitis B 42
Figure 21: Number of Products by argets, Hepatitis D 44
Figure 22: Number of Products by Stage and Targets, Hepatitis D 44
Figure 23: Number of Products by Mechanism of Actions, Hepatitis D 45
Figure 24: Number of Products by Stage and Mechanism of Actions, Hepatitis D 46
Figure 25: Number of Products by Routes of Administration, Hepatitis D 47
Figure 26: Number of Products by Stage and Routes of Administration, Hepatitis D 47
Figure 27: Number of Products by Molecule Types, Hepatitis D 48
Figure 28: Number of Products by Stage and Molecule Types, Hepatitis D 49
Figure 29: Number of Products by Molecule Types, Hepatitis E 50
Figure 30: Number of Products by Stage and Molecule Types, Hepatitis E 51
  • Global Cephalosporin Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 109
    Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections. Cephalosporin originally derived from The fungus Acremonium, which was previously known as "Cephalosporium". The global Cephalosporin market was valued at US$ 1380.7 million in 2023 and is anticipated to reach US$ 1346.9 million by 2030, witnessing a CAGR of -0.3% during The forecast period 2024-2030. Market competition is intense. Qilu Antibiotics, Nectar Lifes......
  • Global Polymixin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 120
    According to our LPI (LP Information) latest study, the global Polymixin market size was valued at US$ 229.9 million in 2023. With growing demand in downstream market, the Polymixin is forecast to a readjusted size of US$ 291 million by 2030 with a CAGR of 3.4% during review period. The research report highlights the growth potential of the global Polymixin market. Polymixin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and sup......
  • Global Sepsis Partnering Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The Sepsis Partnering market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sepsis Partnering market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape......
  • Global Cephalosporin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 156
    According to our LPI (LP Information) latest study, the global Cephalosporin market size was valued at US$ 1350.7 million in 2023. With growing demand in downstream market, the Cephalosporin is forecast to a readjusted size of US$ 1319.6 million by 2030 with a CAGR of -0.3% during review period. The research report highlights the growth potential of the global Cephalosporin market. Cephalosporin are expected to show stable growth in the future market. However, product differentiation, re......
  • Global Amoxicillin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 127
    According to our LPI (LP Information) latest study, the global Amoxicillin market size was valued at US$ 4512.7 million in 2023. With growing demand in downstream market, the Amoxicillin is forecast to a readjusted size of US$ 5711.7 million by 2030 with a CAGR of 3.4% during review period. The research report highlights the growth potential of the global Amoxicillin market. Amoxicillin are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • Global Metronidazole Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 136
    According to our LPI (LP Information) latest study, the global Metronidazole market size was valued at US$ 110.5 million in 2023. With growing demand in downstream market, the Metronidazole is forecast to a readjusted size of US$ 106.6 million by 2030 with a CAGR of -0.5% during review period. The research report highlights the growth potential of the global Metronidazole market. Metronidazole are expected to show stable growth in the future market. However, product differentiation, redu......
  • Global Drugs for Herpes Labialis (Oral Herpes) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131
    According to our LPI (LP Information) latest study, the global Drugs for Herpes Labialis (Oral Herpes) market size was valued at US$ 2404.5 million in 2023. With growing demand in downstream market, the Drugs for Herpes Labialis (Oral Herpes) is forecast to a readjusted size of US$ 3402.2 million by 2030 with a CAGR of 5.1% during review period. The research report highlights the growth potential of the global Drugs for Herpes Labialis (Oral Herpes) market. Drugs for Herpes Labialis (Ora......
  • Global Ampicillin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Ampicillin market size was valued at US$ 161.6 million in 2023. With growing demand in downstream market, the Ampicillin is forecast to a readjusted size of US$ 194.7 million by 2030 with a CAGR of 2.7% during review period. The research report highlights the growth potential of the global Ampicillin market. Ampicillin are expected to show stable growth in the future market. However, product differentiation, reducing costs, a......
  • Global Acinetobacter Infections Treatment Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101
    According to our LPI (LP Information) latest study, the global Acinetobacter Infections Treatment market size was valued at US$ million in 2023. With growing demand in downstream market, the Acinetobacter Infections Treatment is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Acinetobacter Infections Treatment market. Acinetobacter Infections Treatment are expected to show stable ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs